Anacor Pharmaceuticals, Inc. Reports Third Quarter 2014 Financial Results
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2014.
“2014 continues to be a productive year for Anacor. In the third quarter we achieved three important milestones – our first drug, KERYDINTM, was approved by the FDA for the topical treatment of onychomycosis of the toenails; we entered into an exclusive agreement with Sandoz to commercialize KERYDIN in the United States; and finally,
Help employers find you! Check out all the jobs and post your resume.
“2014 continues to be a productive year for Anacor. In the third quarter we achieved three important milestones – our first drug, KERYDINTM, was approved by the FDA for the topical treatment of onychomycosis of the toenails; we entered into an exclusive agreement with Sandoz to commercialize KERYDIN in the United States; and finally,
Help employers find you! Check out all the jobs and post your resume.